Vanguard Reopens Capital Opportunity to Individuals
Fund run by the topnotch Primecap team is still closed to institutions and intermediaries.
Fund run by the topnotch Primecap team is still closed to institutions and intermediaries.
Vanguard announced on Wednesday morning, April 3, that it is reopening the $8.7 billion Vanguard Capital Opportunity (VHCOX) to individual investors and removing the $25,000 annual limit on additional purchases. The fund has been closed to all new investors since March 2004, but the board of directors has decided to allow new "personal investors" to have access to the fund, which has seen $2.6 billion in net outflows over the past three years. However, it will remain closed to all financial advisory, institutional, and intermediary clients, other than those who invest through a Vanguard brokerage account.
Vanguard Capital Opportunity has been managed since 1998 by the Primecap team, which has compiled one of the fund industry's best track records over the past 30 years with Vanguard Primecap (VPMCX). (Since late 2004 it has also managed Vanguard Primecap Core (VPCCX), Primecap Odyssey Growth (POGRX), Primecap Odyssey Stock (POSKX), and Primecap Odyssey Aggressive Growth (POAGX).) Its contrarian growth strategy has also worked very well for Vanguard Capital Opportunity, whose 10-year returns rank in the top 1% of the large-growth category, but it has also made the fund prone to spells of short-term underperformance.
Vanguard Capital Opportunity's most recent dry spell came in 2010 and 2011, when it landed in the category's bottom quartile both years. These problems stemmed largely from big losses by a few prominent holdings, notably Research in Motion (BBRY) and Cree (CREE), though it also didn't help that the portfolio was heavily concentrated in struggling pharma, biotech, and technology names. The managers stuck to their guns, in keeping with their patient, long-term perspective, and that patience has paid off in a big way over the past year. As of April 3, the fund's 22.56% one-year gain is by far the best in the large-growth category. Cree has been one of the biggest contributors, gaining 54% in 2012 and 57% in the first quarter of 2013, and top holding Biogen Idec (BIIB) has also posted big gains after a key drug approval.
This latest period of blowout performance has only confirmed our high opinion of the fund, which earns the top Morningstar Analyst Rating of Gold. Its reopening will give more individual investors access to this fine large-growth offering, though new investors have already been able to buy the same team's similar but more aggressive Primecap Odyssey Growth.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.